Overview

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Lenalidomide
Vaccines